Pages that link to "Q34134986"
Jump to navigation
Jump to search
The following pages link to A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma (Q34134986):
Displaying 50 items.
- New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells (Q26774372) (← links)
- Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding (Q27677425) (← links)
- New investigational drugs with single-agent activity in multiple myeloma (Q28071551) (← links)
- Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling (Q28082335) (← links)
- Trial Watch: Proteasomal inhibitors for anticancer therapy (Q28082910) (← links)
- Recent advances in antimultiple myeloma drug development (Q33416297) (← links)
- Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells (Q33675494) (← links)
- Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 (Q34020937) (← links)
- Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism (Q34079481) (← links)
- The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors (Q34218976) (← links)
- Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses (Q34722352) (← links)
- New insights, recent advances, and current challenges in the biological treatment of multiple myeloma (Q34773850) (← links)
- Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. (Q34788381) (← links)
- Proteasome inhibitors in cancer therapy (Q34939959) (← links)
- Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors (Q35052044) (← links)
- The 26S proteasome complex: an attractive target for cancer therapy (Q35624079) (← links)
- Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis (Q35636675) (← links)
- Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis (Q35764713) (← links)
- The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery (Q35824929) (← links)
- Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside (Q35989980) (← links)
- FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. (Q36293871) (← links)
- The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma (Q36709283) (← links)
- From bortezomib to other inhibitors of the proteasome and beyond (Q36852277) (← links)
- The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases (Q37132187) (← links)
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. (Q37166798) (← links)
- Novel proteasome inhibitors to overcome bortezomib resistance (Q37878771) (← links)
- Latest advances and current challenges in the treatment of multiple myeloma (Q37986287) (← links)
- New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies (Q38002469) (← links)
- Proteasome inhibitors in multiple myeloma: 10 years later (Q38014395) (← links)
- Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development (Q38019864) (← links)
- Molecular mechanisms of effectiveness of novel therapies in multiple myeloma (Q38035044) (← links)
- Emerging biological insights and novel treatment strategies in multiple myeloma (Q38037600) (← links)
- New proteasome inhibitors in myeloma (Q38052079) (← links)
- Mitosis-targeted anti-cancer therapies: where they stand. (Q38053055) (← links)
- Sequential or combination therapy for multiple myeloma (Q38059253) (← links)
- Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib (Q38079578) (← links)
- Proteasome inhibitors in acute leukemia. (Q38088003) (← links)
- Synthesis and pharmacology of proteasome inhibitors (Q38092777) (← links)
- Experimental approaches in the treatment of multiple myeloma (Q38095958) (← links)
- Perspectives in the treatment of multiple myeloma (Q38108391) (← links)
- Current strategies for treatment of relapsed/refractory multiple myeloma (Q38182683) (← links)
- Peptide-based proteasome inhibitors in anticancer drug design. (Q38192572) (← links)
- Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma (Q38202977) (← links)
- An analysis of the safety profile of proteasome inhibitors for treating various cancers (Q38227506) (← links)
- The future of proteasome inhibitors in relapsed/refractory multiple myeloma. (Q38246060) (← links)
- Natural product and natural product derived drugs in clinical trials. (Q38247457) (← links)
- Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials (Q38258843) (← links)
- Role of the ubiquitin proteasome system in hematologic malignancies. (Q38289055) (← links)
- Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma (Q38672091) (← links)
- Novel investigational drugs active as single agents in multiple myeloma. (Q38690290) (← links)